Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Bought by Rafferty Asset Management LLC

Rafferty Asset Management LLC raised its stake in Keros Therapeutics, Inc. (NASDAQ:KROSFree Report) by 12.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,281 shares of the company’s stock after acquiring an additional 7,092 shares during the period. Rafferty Asset Management LLC owned 0.22% of Keros Therapeutics worth $2,596,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of KROS. Franklin Resources Inc. boosted its stake in Keros Therapeutics by 47.9% in the fourth quarter. Franklin Resources Inc. now owns 699,425 shares of the company’s stock valued at $27,809,000 after acquiring an additional 226,674 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Keros Therapeutics by 18.8% during the third quarter. Vanguard Group Inc. now owns 1,406,431 shares of the company’s stock worth $44,837,000 after buying an additional 222,652 shares during the period. Braidwell LP boosted its stake in shares of Keros Therapeutics by 18.7% during the third quarter. Braidwell LP now owns 1,357,309 shares of the company’s stock worth $43,271,000 after buying an additional 213,444 shares during the period. UBS Group AG boosted its stake in shares of Keros Therapeutics by 2,653.7% during the fourth quarter. UBS Group AG now owns 181,385 shares of the company’s stock worth $7,212,000 after buying an additional 174,798 shares during the period. Finally, WCM Investment Management LLC boosted its stake in shares of Keros Therapeutics by 58.6% during the fourth quarter. WCM Investment Management LLC now owns 154,664 shares of the company’s stock worth $6,349,000 after buying an additional 57,122 shares during the period. Institutional investors and hedge funds own 71.56% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Piper Sandler reiterated an “overweight” rating and set a $105.00 target price on shares of Keros Therapeutics in a research note on Wednesday, March 27th. Truist Financial reiterated a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a research note on Wednesday, March 13th. William Blair reiterated an “outperform” rating on shares of Keros Therapeutics in a research note on Wednesday, February 21st. HC Wainwright reissued a “buy” rating and set a $100.00 price target on shares of Keros Therapeutics in a report on Thursday, May 9th. Finally, Wedbush reissued an “outperform” rating and set a $86.00 price target on shares of Keros Therapeutics in a report on Thursday, February 29th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Keros Therapeutics has a consensus rating of “Buy” and an average target price of $86.00.

Get Our Latest Analysis on Keros Therapeutics

Keros Therapeutics Price Performance

NASDAQ KROS opened at $48.69 on Friday. Keros Therapeutics, Inc. has a 52-week low of $27.02 and a 52-week high of $73.00. The stock has a market capitalization of $1.76 billion, a P/E ratio of -9.45 and a beta of 1.24. The firm has a 50-day moving average price of $55.59 and a 200 day moving average price of $52.84.

Keros Therapeutics (NASDAQ:KROSGet Free Report) last issued its earnings results on Wednesday, May 8th. The company reported ($1.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.33) by $0.12. The company had revenue of $0.08 million during the quarter. During the same period in the previous year, the business posted ($1.26) earnings per share. The company’s quarterly revenue was down 97.3% compared to the same quarter last year. On average, equities research analysts expect that Keros Therapeutics, Inc. will post -4.97 earnings per share for the current fiscal year.

Keros Therapeutics Company Profile

(Free Report)

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

Further Reading

Institutional Ownership by Quarter for Keros Therapeutics (NASDAQ:KROS)

Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.